Program
This edition will feature the following themes:
- Alternative to current antibiotics & antivirals
- Immunotherapies & new biotherapeutics
- One Health Approach to Tackling Infectious Diseases
- Innovations in human vaccines
- AI & Data-Driven Strategies for Infectious Diseases
- Innovative Biomarkers for Infectious Diseases: From Diagnosis to Theragnosis
2025 Speaker
Erin Duffy
Chief of Research & Development
CARB-X, USA
Lisa Osbelt-Block
Researcher
Helmholtz Center for Infection Research, Germany
Vincent Marechal
Professor
Sorbonne University
Director
National platform OBEPINE+
Mélanie Hamon
Head of the Chromatin and Infection group
Institut Pasteur, France
Helen Bright
CSO
Centauri Therapeutics, United Kingdom
Nicolas Burdin
Global Head of R&D
CloverBiopharmaceuticals, France
Victoria Savage
CSO
Infex Therapeutics Ltd, United Kingdom
Stuart Hannah
CEO
Microplate Dx, Scotland
Khaled Abousaleh
CEO
Zynnon, Switzerland
DAY 1
Thursday, 13 November 2025
8h00
Registration & welcome coffee
8h30
Welcome Address
8h45
Opening lectures
- Plenary
Chaired by
9h15
Modelling to support new TB Vaccine development and (hopefully) introduction
Richard White
Professor of Infectious Disease Modelling
London School of Hygiene and Tropical Medicine, United Kingdom
9h45
Decoding Mycobacterium tuberculosis Diversity: Unlocking New Strategies in TB Control
Sarah Fortune
Chair of Immunology and Infectious Diseases
Harvard T.H. Chan School of Public Health, USA
10h15
Coffe Break - Exhibition Hall - B2B Meetings
10h45
Track 1: One Health Approach to Tackling Infectious Diseases
- Plenary
Chaired by
10h45
OH should be embedded in health policies and strategies
Thierry Lefrançois
Advisor to the CEO
CIRAD, France
11h15
OBEPINE+ platform: tracking epidemics through wastewater analysis
Vincent Marechal
Professor of virology
Sorbonne University, France
Director
National platform OBEPINE+, France
11h35
Title to be confirmed
Agnès Dancer
R&D Project Manager
Boehringer Ingelheim - France
11h25
Speaker 3
Yves Briers
CSO
Obulytix - Belgium
11h55
Q&A session
12h00
Lunchbreak - Poster Presentation - B2B Meetings
14h00
Track 2: Innovations in human vaccines
- Plenary
Sponsored by Sanofi
Chaired by
14h00
Clover’s Trimer-Tag vaccines: COVID, RSV and beyond…
Nicolas Burdin
Global Head of R&D
Clover Biopharmaceuticals, France
14h40
The transformative role of open-access adjuvants for human vaccines
Céline Lemoine
Head of VFI Laboratories
Vaccine Formulation Institute (VFI) - Switzerland
15h00
Speaker 4
Stephanie Fanucchi
CSO
Lemba Therapeutics - Netherlands
15h20
Q&A session
15h35
Coffe Break - Exhibition Hall - B2B Meetings 3 slots
16h10
Driving Breakthroughs in Infectious Diseases
16h10
Title to be confirmed
Christine Duthoit
CEO - CSO
RNAlead - France
16h25
Addressing Delivery Barriers in RNA-based Vaccines through the FlashRNA® Platform
Christine Duthoit
CEO - CSO
RNAlead - France
18h00
End of DAY 1
DAY 2
Friday, 14 November 2025
8h30
Welcome coffee
9h00
Opening lectures
- Plenary
Chaired by
10h00
Keynote lecture Jean Kaseya - Africa CDC - Ethiopia
Jean Kaseya
Professor
Imperial college London - United Kingdom
Karolinska Institute - Sweden
9h15
Fighting Antimicrobial Resistance Through Innovation
Erin Duffy
Chief of Research & Development
CARB-X, USA
10h30
Coffe Break - Exhibition Hall - B2B Meetings
11h00
Track 3: Immunotherapies & new biotherapeutics
- Plenary
Chaired by
11h00
How bacterial pathogens manipulate host chromatin to modulate immune responses?
Mélanie Hamon
Head of the Chromatin and Infection group
Institut Pasteur, France
11h20
Alphamer®: A Modular Antibody-Recruiting Platform for Infectious Disease
David Chapman
Head of Biology
Centauri Therapeutics, United Kingdom
11h40
RESP-X: A Novel Anti-Virulence Therapy Targeting Pseudomonas aeruginosa in Chronic Infection
Victoria Savage
CSO
Infex Therapeutics Ltd, United Kingdom
12h00
Q&A session
12h15
Lunchbreak - Poster Presentation - B2B Meetings
14h00
Track 4: Alternative to current antibiotics & antivirals
- Plenary
Chaired by
14h00
Competition in the gut: From ecology to novel therapeutics
Lisa Osbelt-Block
Researcher
Helmholtz Center for Infection Research, Germany
14h20
Small Molecule FPR1 Agonists: Boosting the Innate Immune System to Cure Resistant Bacterial Infections
Peter Olofsson-Sahl
Founder and CEO
Inicure AB, Sweden
14h40
RNAs in bacteria-phage interactions: from identification to applications for biotechnology and health
Olga Soutourina
Professor in Microbiology
Paris-Saclay University - France
15h00
Q&A session
15h15
Track 5: Innovative Biomarkers for Infectious Diseases: From Diagnosis to Theragnosis
- Plenary
Chaired by
15h15
RapidPlateTM: A novel, cost-effective, electrochemical, rapid antibiotic susceptibility test for urinary tract infections
Stuart Hannah
CEO
Microplate Dx, Scotland
15h35
Revolutionizing Infectious Disease Diagnostics Through Gas Signatures
Khaled Abousaleh
CEO
Zynnon, Switzerland
15h55
Speaker 3
Antonella Comforti
Principal Investigator
Takis Biotech - Italy
16h15
Q&A session
16h10
Annoucemment of next year edition
16h20
